“Well on the border tax … we are a net exporter. So that’s positive, certainly as the lowering of the U.S. rate would be positive. It all depends on all of the other factors that go in it, and that’s very volatile in terms of what other factors there might be such as the interest expense and the price of repatriation of unremitted foreign earnings. So it’s too quick and too soon to know because it’s anybody’s guess as to what will actually end up in the ultimate rules, and we still got a way to go. But there’s some positive, there’s some negative, we’ll see where they come out. But the one thing that I would want you to take away is that we are a net exporter. We do have over 30 plants in the U.S., so we feel good about that aspect of it.” —BD chief financial officer Chris Reidy, Feb. 2
About The Author
Chris Newmarker
Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.